Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients-Reference-Cited by-同舟云学术

Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients

Published:2017-02 Issue: Volume:31 Page:186-191
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Coltelli Luigi,Fontana Andrea,Lucchesi Sara,Ginocchi Laura,Bocci Guido,Filidei Mario,Scalese Marco,Arrighi Giada,Finale Chiara,Marcucci Lorenzo,Goletti Orlando,Salvadori Barbara,Ferrarini Ilaria,Bona Eleonora,Falcone Alfredo,Allegrini Giacomo

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference35 articles.

1. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast Cancer: the international breast Cancer study group trial VII;Crivellari;J Clin Oncol,2000

2. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials;Peto;Lancet,2012

3. Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women;Hebert-Croteau;Cancer,1999

4. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

5. Chemotherapy and cardiotoxicity in older breast Cancer patients: a population-based study;Doyle;J Clin Oncol,2005

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer;JACC: CardioOncology;2024-04

2. Liposomal and Liposomes-Film Systems as Carriers for Bioactives from Paeonia tenuifolia L. Petals: Physicochemical Characterization and Biological Potential;Pharmaceutics;2023-12-07

3. Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study;Clinical and Experimental Medicine;2023-08-27

4. Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis;Cancer Medicine;2023-05-06

5. Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer;Cancers;2021-09-01